Session Type: ACR Concurrent Abstract Session
Session Time: 4:30PM-6:00PM
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy (NCT01796301).
Conclusion: In subjects transitioning from bisphosphonate therapy, romosozumab was well-tolerated and was associated with significant BMD gains at both the hip and spine compared with teriparatide. BMD gains in the cortical compartment contributed to the greater treatment effect of romosozumab at the hip. Estimated hip strength improved with romosozumab over 12 months but decreased early with teriparatide. A global phase 3 program evaluating romosozumab for the treatment of postmenopausal osteoporosis is ongoing.
To cite this abstract in AMA style:Langdahl B, Libanati C, Crittenden D, Bolognese M, Brown J, Daizadeh N, Engelke K, Genant H, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny T, Kendler D, Lakatos P, Maddox J, Malouf J, Massari F, Molina J, Ulla M, Grauer A. Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/superior-gains-in-bone-mineral-density-and-estimated-strength-at-the-hip-for-romosozumab-compared-with-teriparatide-in-women-with-postmenopausal-osteoporosis-transitioning-from-bisphosphonate-therapy/. Accessed December 2, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/superior-gains-in-bone-mineral-density-and-estimated-strength-at-the-hip-for-romosozumab-compared-with-teriparatide-in-women-with-postmenopausal-osteoporosis-transitioning-from-bisphosphonate-therapy/